Windtree Therapeutics Inc (NASDAQ: WINT)’s stock price has decreased by -6.52 compared to its previous closing price of 0.32. However, the company has seen a -18.42% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-09 that WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that it has filed a new istaroxime PCT patent application entitled, “ISTAROXIME DERIVATIVES THEREOF FOR PREVENTING OR REDUCING THE RISK OF ACUTE MYOCARDIAL ARRHYTHMIA.”
Is It Worth Investing in Windtree Therapeutics Inc (NASDAQ: WINT) Right Now?
The 36-month beta value for WINT is also noteworthy at 0.56. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for WINT is 8.94M, and at present, short sellers hold a 5.56% of that float. The average trading volume of WINT on December 26, 2024 was 1.67M shares.
WINT’s Market Performance
The stock of Windtree Therapeutics Inc (WINT) has seen a -18.42% decrease in the past week, with a -38.37% drop in the past month, and a -89.31% fall in the past quarter. The volatility ratio for the week is 8.84%, and the volatility levels for the past 30 days are at 11.77% for WINT. The simple moving average for the last 20 days is -25.90% for WINT stock, with a simple moving average of -92.45% for the last 200 days.
Analysts’ Opinion of WINT
Many brokerage firms have already submitted their reports for WINT stocks, with Ladenburg Thalmann repeating the rating for WINT by listing it as a “Buy.” The predicted price for WINT in the upcoming period, according to Ladenburg Thalmann is $12.25 based on the research report published on June 26, 2020 of the previous year 2020.
WINT Trading at -47.20% from the 50-Day Moving Average
After a stumble in the market that brought WINT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.94% of loss for the given period.
Volatility was left at 11.77%, however, over the last 30 days, the volatility rate increased by 8.84%, as shares sank -45.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -55.32% lower at present.
During the last 5 trading sessions, WINT fell by -20.05%, which changed the moving average for the period of 200-days by -95.82% in comparison to the 20-day moving average, which settled at $0.4097. In addition, Windtree Therapeutics Inc saw -97.60% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at WINT starting from Fraser Craig, who purchase 5,431 shares at the price of $0.91 back on Oct 08 ’24. After this action, Fraser Craig now owns 8,638 shares of Windtree Therapeutics Inc, valued at $4,942 using the latest closing price.
Stock Fundamentals for WINT
The total capital return value is set at -1.6. Equity return is now at value -138.34, with -29.19 for asset returns.
Based on Windtree Therapeutics Inc (WINT), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -12.21. The debt to equity ratio resting at 0.28. The interest coverage ratio of the stock is -137.4.
Currently, EBITDA for the company is -20.16 million with net debt to EBITDA at 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.27.
Conclusion
In summary, Windtree Therapeutics Inc (WINT) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
